Clinical trial
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or…
NCT00049686 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00049686 |
|---|---|
| Title | VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome |
| Official title | A Phase I Trial Of VNP40101M, A Novel Alkylating Agent, For Patients With Hematologic Malignancies |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Drug |
| Interventions | laromustine |
| Start date | Apr 1, 2002 |
| Completion | Jan 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: